News About: Pharm. Industry
Companies To Raise Prices of Nicotine Replacement Products
In the midst of an announced cigarette price increase by 500 won starting next year, the pharmaceutical companies are simultaneously planning to raise the prices for their nicotine replacement products.
According t...
Eroding Profitability of Domestic Pharmaceutical Firms
The domestic pharmaceutical manufacturers are showing an overall growth in sales, but are suffering from margin erosions and lower profitability, reported by the Korea Health Industry Development Institute (KHIDI) fro...
CJ Filed Injunction To End Trademark Dispute
In an effort to put a final closure on its controversial trademark dispute with Hanmi Pharmaceutical, CJ Pharmaceutical Division filed for an injunction with the Seoul Central District Court on December 6th.
The Ko...
Novartis Korea Launches Domestic Phase 3 Clinical Trial of Aliskiren
Novartis Korea announced on December 9th that the international Phase 3 clinical trial of its anti-hypertension drug Aliskiren (SPP100), a renin inhibitor, will also take place in Korea along with four other countries...
Arimidex Continues To Show Better Efficacy Over Tamoxifen
AstraZeneca announced on December 9th the results of the ATAC (Arimidex and Tamoxifen Alone or in Combination) study presented at the 27th San Antonio Breast Cancer Symposium, which showed that Arimidex (anastrozole; ...
Pharmaceutical and Biotech Companies Share Partnering Ideas & Technologies
The Bio Business & Partnering Forum, sponsored by the Korea Health Industry Development Institute (KHIDI), was recently completed with success, where many domestic pharmaceutical and biotechnology companies actively s...
Yuhan Corporation Receives ‘Top Pick’ by Market Research Firm
According to ‘Year 2005 Pharmaceutical Industry Forecast’ by Sejong Securities, the overall market condition of domestic pharmaceutical industry will improve throughout next year, supported by a number of positive mar...
Bukwang Signs with Dainippon for Blonanserin
Bukwang Pharmaceuticals announced the signing of a Letter of Intent (LOI) with Dainippon Pharmaceutical Co. Ltd. that provides Bukwang with exclusive licensing rights for blonanserin, an original antipsychotic agent f...
Hanmi’s President Receives Top CEO of The Year AwardPresident & CEO Min Kyung-yoon of Hanmi Pharmaceuticals received the Top CEO of the Year Award hosted by the Korean Society of Chief Executive Officers. This award came shortly...
|
Number of Licensed Medical Representatives Increase to 1,150
The total number of licensed medical representatives (MR) has now become 1,150 as reported by the MR License Center of the Korean Pharmaceutical Manufacturers Association (KPMA).
About 120 pharmaceutical companie...
